Selway Asset Management Has $3.31 Million Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Selway Asset Management boosted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) by 21.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,059 shares of the medical equipment provider’s stock after purchasing an additional 4,420 shares during the period. Zimmer Biomet accounts for approximately 1.3% of Selway Asset Management’s portfolio, making the stock its 28th biggest position. Selway Asset Management’s holdings in Zimmer Biomet were worth $3,307,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. OLD Point Trust & Financial Services N A bought a new stake in shares of Zimmer Biomet in the 4th quarter valued at approximately $26,000. Ables Iannone Moore & Associates Inc. bought a new position in shares of Zimmer Biomet during the 4th quarter valued at $30,000. Naples Money Management LLC bought a new stake in Zimmer Biomet in the fourth quarter worth $35,000. Activest Wealth Management increased its position in Zimmer Biomet by 410.4% during the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider’s stock worth $42,000 after buying an additional 275 shares during the last quarter. Finally, Blue Trust Inc. raised its holdings in Zimmer Biomet by 48.4% during the fourth quarter. Blue Trust Inc. now owns 469 shares of the medical equipment provider’s stock valued at $52,000 after buying an additional 153 shares in the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

ZBH has been the topic of a number of analyst reports. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Thursday, May 30th. Argus upgraded Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a report on Tuesday, May 21st. Evercore ISI boosted their price objective on shares of Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. Barclays lowered their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating on the stock in a research note on Friday, May 31st. Finally, Citigroup boosted their target price on shares of Zimmer Biomet from $134.00 to $140.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. One research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $133.75.

Read Our Latest Stock Report on ZBH

Zimmer Biomet Stock Performance

Shares of ZBH traded up $1.61 on Friday, reaching $107.86. 3,444,108 shares of the stock traded hands, compared to its average volume of 1,481,483. The stock’s 50-day moving average price is $116.92 and its 200-day moving average price is $121.54. The firm has a market cap of $22.19 billion, a price-to-earnings ratio of 23.07, a P/E/G ratio of 1.92 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $147.50. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.66 and a quick ratio of 0.80.

Zimmer Biomet (NYSE:ZBHGet Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.07. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The firm had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. During the same quarter in the prior year, the business posted $1.89 earnings per share. The company’s quarterly revenue was up 3.2% compared to the same quarter last year. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 31st. Shareholders of record on Wednesday, June 26th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date of this dividend is Wednesday, June 26th. Zimmer Biomet’s dividend payout ratio (DPR) is 20.78%.

Zimmer Biomet Profile

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Further Reading

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.